Ratings Ambea AB

Equities

AMBEA

SE0009663826

Market Closed - Nasdaq Stockholm Other stock markets 11:29:49 2024-04-26 am EDT			5-day change	1st Jan Change
63.4 ^SEK	+1.93%		-0.86%	+20.53%

Apr. 12	Ambea AB Proposes Dividend, Payable on 22 May 2024	CI
Mar. 13	Triton Fund III-controlled ACTR Trims Ambea Shareholding via Share Placement	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's attractive earnings multiples are brought to light by a P/E ratio at 11.31 for the current year.
The company's share price in relation to its net book value makes it look relatively cheap.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AMBEA AB	+20.53%	518M		B-
CVS HEALTH CORPORATION	-14.92%	84.68B		B-
HCA HEALTHCARE, INC.	+13.30%	81.12B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B		B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B		A-
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B		A-
PURE HEALTH HOLDING	-31.75%	11.77B	-	-
FRESENIUS MEDICAL CARE AG	-1.42%	11.72B		A-
DAVITA INC.	+27.44%	11.71B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes